Shares of Editas Medicine Inc. (Nasdaq: EDIT) tumbled $1.87 to close at $13.75 after a scientific paper published in Nature Methods warned of unintended genetic mutations in mice that had been cured of blindness using CRISPR/Cas9.
Unintended mutations from CRISPR technology
May 30, 2017 at 18:34 PM EDT
